CRSP CRISPR Therapeutics AG Stock Quote

CRSP [NASD]

Healthcare | Biotechnology | Switzerland

Index	-	P/E	-	EPS (ttm)	-3.25	Insider Own	1.20%	Shs Outstand	70.14M	Perf Week	-13.61%
Market Cap	11.90B	Forward P/E	-	EPS next Y	-5.31	Insider Trans	-41.97%	Shs Float	64.11M	Perf Month	-2.70%
Income	-211.30M	PEG	-	EPS next Q	-1.27	Inst Own	75.60%	Short Float	6.04%	Perf Quarter	74.17%
Sales	77.40M	P/S	153.76	EPS this Y	134.10%	Inst Trans	15.14%	Short Ratio	2.18	Perf Half Y	89.76%
Book/sh	19.15	P/B	8.56	EPS next Y	-5.80%	ROA	-18.40%	Target Price	146.56	Perf Year	196.26%
Cash/sh	18.82	P/C	8.71	EPS next 5Y	-	ROE	-20.70%	52W Range	32.30 - 220.20	Perf YTD	7.08%
Dividend	-	P/FCF	-	EPS past 5Y	54.00%	ROI	4.90%	52W High	-25.54%	Beta	2.38
Dividend %	-	Quick Ratio	16.50	Sales past 5Y	-	Gross Margin	-	52W Low	407.59%	ATR	13.98
Employees	304	Current Ratio	16.50	Sales Q/Q	-100.00%	Oper. Margin	-	RSI (14)	44.28	Volatility	7.59% 8.27%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-154.80%	Profit Margin	-	Rel Volume	1.95	Prev Close	169.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Oct 28 BMO	Payout	-	Avg Volume	1.78M	Price	163.95
Recom	2.40	SMA20	-9.11%	SMA50	7.15%	SMA200	67.29%	Volume	3,467,481	Change	-3.29%

Dec-10-20

Reiterated

Needham

Buy

$105 → $170

Dec-10-20

Reiterated

Chardan Capital Markets

Buy

$110 → $166

Dec-10-20

Downgrade

Jefferies

Buy → Hold

Dec-07-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$145

Oct-23-20

Initiated

RBC Capital Mkts

Sector Perform

$110

Oct-05-20

Initiated

BofA Securities

Buy

$110

Jul-28-20

Reiterated

Needham

Buy

$84 → $105

Jul-14-20

Initiated

SunTrust

Buy

$140

Jun-15-20

Reiterated

Canaccord Genuity

Buy

$80 → $84

Mar-05-20

Initiated

Stifel

Hold

$52

Feb-03-20

Downgrade

Evercore ISI

Outperform → In-line

$85 → $52

Nov-19-19

Upgrade

William Blair

Mkt Perform → Outperform

Nov-12-19

Upgrade

Oppenheimer

Perform → Outperform

$65

Aug-01-19

Initiated

Jefferies

Buy

$64

Jul-26-19

Initiated

Canaccord Genuity

Buy

$72

Jun-10-19

Initiated

ROTH Capital

Buy

$50

Apr-12-19

Initiated

Evercore ISI

Outperform

Mar-14-19

Initiated

William Blair

Mkt Perform

Jan-28-19

Downgrade

Goldman

Buy → Neutral

Jan-22-19

Downgrade

Citigroup

Neutral → Sell

Jan-21-21 02:43PM	ARK ETFs Might Be Too Popular for Their Own Good Barrons.com
Jan-20-21 08:23AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics Zacks
Jan-19-21 10:46AM	CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why Zacks
Jan-18-21 08:41AM	Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why Zacks
Jan-15-21 06:12PM	7 CRISPR Stocks for the Future of Medicine InvestorPlace
Jan-14-21 03:11PM	With Rare Speed, Gene Editing Emerges as Biotechs New Cutting Edge Barrons.com +8.36%
01:22PM	CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Now TheStreet.com
Jan-12-21 01:24PM	Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301 Zacks
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-08-21 09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks
Jan-07-21 04:24PM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs Investor's Business Daily +18.66%
10:38AM	Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU Zacks
08:42AM	3 Biotech Technological Developments to Watch Out For in 2021 Zacks
Jan-06-21 02:25PM	CRISPR Therapeutics Is Still Looking Strong TheStreet.com
11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age Barrons.com
Jan-01-21 02:42PM	10 Best Stocks To Buy and Hold For 5 Years According To ARKs Cathie Wood Insider Monkey
Dec-29-20 12:27PM	Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today Motley Fool -6.57%
Dec-23-20 07:29PM	12 Best Genomic Stocks to Buy Now Insider Monkey
Dec-22-20 03:00PM	Cutting Edge CRISPR Therapeutics Has Cut a Path Higher TheStreet.com
10:01AM	Return On Capital Employed Overview: CRISPR Therapeutics Benzinga
09:48AM	5 Medical Outperformers That Might Lose Steam in 2021 Zacks
Dec-21-20 04:24PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives Investor's Business Daily +12.27%
12:12PM	Why Editas Medicine Stock Is Skyrocketing Today Motley Fool
08:43AM	3 Biotech Stocks That Could Explode Higher in 2021 Motley Fool
Dec-16-20 05:17AM	Megatrends To Invest In Now: 3 Best ETF Picks Investor's Business Daily Video
Dec-15-20 07:03AM	Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Dec-14-20 08:00AM	CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV GlobeNewswire
Dec-13-20 06:45AM	If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks Now Motley Fool
02:04AM	Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth Simply Wall St.
Dec-12-20 03:39PM	Watch Out bluebird bio, CRISPR Is on Your Heels Motley Fool
Dec-10-20 02:03PM	CRISPR Gene Editing: Owning the Future of Medicine Zacks +5.20%
01:45PM	Is CRISPR Therapeutics Heading for $170? Motley Fool
12:47PM	Editas (EDIT) Submits Application to Start Study on EDIT-301 Zacks
Dec-09-20 01:10PM	Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News Zacks
11:27AM	Why Editas Medicine Stock Is Rising for a Third Consecutive Day Motley Fool
Dec-08-20 04:45PM	The Latest Lap in Bluebirds and Crisprs Race to Cure Sickle Cell Barrons.com
08:44AM	Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock? Zacks
Dec-07-20 04:20PM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily
09:19AM	CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001 Zacks
Dec-05-20 12:30PM	CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine GlobeNewswire
Dec-01-20 09:00AM	CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 in Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Nov-24-20 08:00AM	CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-21-20 06:33AM	Is Gene Editing Already Leaving CRISPR Therapeutics Behind? Motley Fool
Nov-20-20 09:17AM	Volatility May Continue, But CRISPR Stock Remains a Buy InvestorPlace
Nov-16-20 08:00AM	CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-14-20 05:24AM	3 Best Biotech Stocks to Buy Right Now Motley Fool
Nov-07-20 07:04AM	Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs Motley Fool
Nov-04-20 04:17PM	Why This Gene-Editing Player Just Outpaced Bullish Biotech Stocks Investor's Business Daily +10.01%
03:16PM	Why This Gene-Editing Player Just Outpaced Bullish Biotech Stocks Investor's Business Daily
02:11PM	CRISPR and Vertex Release Additional Data for Blood Disease Treatment Motley Fool
09:15AM	CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition GlobeNewswire
Nov-02-20 07:34AM	Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode Motley Fool -6.16%
Oct-31-20 06:43AM	2 Monster Young Biotech Stocks to Add to Your Watchlist Motley Fool
Oct-29-20 08:51AM	Did The Underlying Business Drive CRISPR Therapeutics' (NASDAQ:CRSP) Lovely 407% Share Price Gain? Simply Wall St.
Oct-28-20 04:59PM	CRISPR Therapeutics Stock Falls 3.5% on Q3 Results Motley Fool
08:00AM	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-24-20 08:55AM	Is CRISPR Therapeutics a Good Biotech Stock to Buy Now? Motley Fool
Oct-22-20 05:41PM	Is CRISPR Therapeutics Really Headed to $110? Motley Fool
01:11PM	CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study Zacks
11:22AM	Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates Zacks
Oct-21-20 05:58PM	CRISPR Therapeutics Reports Mixed Cancer Trial Results Motley Fool -13.57%
04:26PM	Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial Investor's Business Daily
12:19PM	Why CRISPR Therapeutics Stock Sank Today Motley Fool
10:02AM	Crispr Therapeutics Gene-Edited Treatment Stopped Cancer in Some Patients Barrons.com
08:04AM	The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga
07:00AM	CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell Malignancies GlobeNewswire
Oct-16-20 12:12PM	3 Biotech Stocks to Buy Right Now InvestorPlace +9.95%
Oct-15-20 11:18AM	Why You Should Invest in Genomics ETFs Zacks
Oct-12-20 09:45AM	Booming Gene Editing Market to Pep Up These 5 Biotech Stocks Zacks
Oct-09-20 10:14AM	The Innovative Future Of ETFs Zacks
Oct-08-20 01:31PM	Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers Zacks
Oct-07-20 06:05PM	Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel Zacks +11.35%
10:04AM	Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks Barrons.com
09:26AM	CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry GlobeNewswire
Oct-05-20 02:23PM	Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts TheStreet.com +8.89%
12:28PM	Crispr's stock shoots up after bullish call from BofA Securities analyst MarketWatch
Sep-30-20 06:45AM	Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
Sep-29-20 08:00AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-24-20 06:04AM	3 Stocks That Could Double Your Money Motley Fool
Sep-23-20 11:03AM	CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status Zacks
Sep-22-20 09:00AM	CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Sep-15-20 11:00AM	Hedge Funds Are Done Buying CRISPR Therapeutics AG (CRSP) Insider Monkey
Sep-14-20 07:20AM	How Much Does CRISPR Therapeutics' (NASDAQ:CRSP) CEO Make? Simply Wall St. +5.91%
Sep-10-20 06:55AM	2 Game-Changing Biotech Stocks That May Make You Rich Motley Fool
Sep-09-20 05:26PM	CRISPR Stocks: Buy or Trade? Zacks
07:04AM	Is CRISPR Therapeutics Stock a Good Buy Now, or Is It Too Late? Motley Fool
Sep-03-20 08:00AM	CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire -8.77%
Aug-26-20 11:30AM	CRISPR Therapeutics AG (CRSP) Up 2.9% Since Last Earnings Report: Can It Continue? Zacks
Aug-20-20 08:33AM	CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher Zacks -8.82%
Aug-18-20 11:41AM	CRISPR Therapeutics Stock Shows It Has Good Genes TheStreet.com
Jul-30-20 08:00AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-29-20 06:53AM	Industry Analysts Just Made A Meaningful Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Revenue Forecasts Simply Wall St.
Jul-28-20 03:53AM	Crispr Therapeutics Down 4% On Earnings Miss; Street Stays Bullish SmarterAnalyst -6.21%
Jul-27-20 06:15PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:01PM	Crisper Therapeutics shares decline on wider-than-expected loss MarketWatch
04:30PM	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
12:31PM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know Zacks
10:18AM	What's in Store for CRISPR (CRSP) This Earnings Season? Zacks
Jul-26-20 08:10AM	If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now Motley Fool
Jul-25-20 11:52AM	Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases. Barrons.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KASINGER JAMES R.	General Counsel and Secretary	Jan 19	Option Exercise	51.49	27,500	1,415,975	49,931	Jan 20 06:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Jan 19	Sale	204.94	27,500	5,635,944	22,431	Jan 20 06:05 PM
Klein Lawrence Otto	CBO & COO	Jan 15	Option Exercise	13.79	25,010	344,776	36,334	Jan 20 06:07 PM
Kulkarni Samarth	Chief Executive Officer	Jan 15	Option Exercise	1.81	20,000	36,200	202,989	Jan 20 06:11 PM
Klein Lawrence Otto	CBO & COO	Jan 15	Sale	215.20	25,000	5,379,940	20,000	Jan 20 06:07 PM
Kulkarni Samarth	Chief Executive Officer	Jan 15	Sale	213.67	20,000	4,273,311	182,989	Jan 20 06:11 PM
Kulkarni Samarth	Chief Executive Officer	Dec 29	Option Exercise	1.81	13,800	24,978	182,989	Dec 30 04:02 PM
Ho Tony W	Executive VP, Head of R&D	Dec 21	Option Exercise	16.90	23,551	398,012	57,515	Dec 22 04:55 PM
Ho Tony W	Executive VP, Head of R&D	Dec 21	Sale	149.23	23,551	3,514,610	33,964	Dec 22 04:55 PM
Bolzon Bradley J PhD	Director	Dec 16	Sale	148.95	7,352	1,095,089	339,834	Dec 18 07:12 PM
Bolzon Bradley J PhD	Director	Dec 16	Sale	148.95	7,648	1,139,177	0	Dec 18 07:12 PM
Kulkarni Samarth	Chief Executive Officer	Dec 10	Option Exercise	1.81	20,000	36,200	189,189	Dec 11 04:05 PM
Kulkarni Samarth	Chief Executive Officer	Dec 10	Sale	142.29	20,000	2,845,782	169,189	Dec 11 04:05 PM
Bolzon Bradley J PhD	Director	Dec 10	Sale	143.35	33,000	4,730,448	314,186	Dec 14 07:11 PM
KASINGER JAMES R.	General Counsel and Secretary	Dec 09	Option Exercise	13.62	22,026	299,994	22,415	Dec 10 04:35 PM
Bolzon Bradley J PhD	Director	Dec 07	Sale	154.53	171,004	26,424,505	347,186	Dec 09 07:54 PM
Novak Rodger	President	Nov 30	Option Exercise	14.22	100,000	1,421,500	698,007	Dec 02 04:26 PM
Novak Rodger	President	Nov 30	Sale	125.00	100,000	12,500,000	648,007	Dec 02 04:26 PM
Novak Rodger	President	Oct 09	Option Exercise	14.43	2,762	39,856	650,769	Oct 13 04:44 PM
Novak Rodger	President	Oct 09	Sale	100.00	2,762	276,200	648,007	Oct 13 04:44 PM
Novak Rodger	President	Oct 08	Option Exercise	14.43	22,238	320,894	670,245	Oct 13 04:44 PM
Novak Rodger	President	Oct 08	Sale	100.00	22,238	2,223,800	648,007	Oct 13 04:44 PM
Bolzon Bradley J PhD	Director	Sep 18	Sale	86.87	3,035	263,636	518,190	Sep 22 08:10 PM
Bolzon Bradley J PhD	Director	Sep 16	Sale	86.98	8,965	779,777	521,225	Sep 18 04:30 PM
Bolzon Bradley J PhD	Director	Sep 14	Sale	84.89	1,155	98,045	530,190	Sep 16 08:00 PM
Bolzon Bradley J PhD	Director	Sep 10	Sale	85.36	22,845	1,949,996	531,345	Sep 11 09:49 PM
Bolzon Bradley J PhD	Director	Sep 01	Option Exercise	25.23	60,000	1,513,950	60,000	Sep 03 09:21 PM
Novak Rodger	President	Sep 01	Option Exercise	14.36	25,000	359,059	673,007	Sep 03 04:44 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Sep 01	Option Exercise	17.75	12,000	213,000	12,410	Sep 03 04:46 PM
Novak Rodger	President	Sep 01	Sale	92.62	25,000	2,315,578	648,007	Sep 03 04:44 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Sep 01	Sale	92.26	12,000	1,107,068	410	Sep 03 04:46 PM
Bolzon Bradley J PhD	Director	Sep 01	Sale	92.51	60,000	5,550,644	0	Sep 03 09:21 PM
Novak Rodger	President	Aug 19	Option Exercise	14.00	25,000	350,000	673,007	Aug 21 04:11 PM
Novak Rodger	President	Aug 19	Sale	100.00	25,000	2,500,000	648,007	Aug 21 04:11 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Aug 03	Option Exercise	17.75	12,000	213,000	12,410	Aug 05 04:20 PM
TOMSICEK MICHAEL JOHN	Chief Financial Officer	Aug 03	Sale	86.74	12,000	1,040,919	410	Aug 05 04:20 PM
Novak Rodger	President	Jul 07	Option Exercise	11.28	25,000	281,907	673,007	Jul 09 04:00 PM
Novak Rodger	President	Jul 07	Sale	90.00	25,000	2,250,000	648,007	Jul 09 04:00 PM
Bolzon Bradley J PhD	Director	Jul 06	Sale	82.39	20,000	1,647,730	554,190	Jul 08 04:00 PM
Novak Rodger	President	Jul 01	Sale	80.00	50,000	4,000,000	648,007	Jul 06 04:14 PM
Klein Lawrence Otto	CBO & COO	Jun 25	Option Exercise	12.57	4,912	61,744	24,912	Jun 26 04:33 PM
Klein Lawrence Otto	CBO & COO	Jun 25	Sale	75.18	4,912	369,272	20,000	Jun 26 04:33 PM
Klein Lawrence Otto	CBO & COO	Jun 24	Option Exercise	8.58	65,088	558,707	58,666	Jun 26 04:33 PM
Klein Lawrence Otto	CBO & COO	Jun 24	Sale	75.93	65,088	4,942,292	20,000	Jun 26 04:33 PM
Novak Rodger	President	Jun 23	Sale	75.00	50,000	3,750,000	698,007	Jun 25 04:28 PM
Bolzon Bradley J PhD	Director	Jun 23	Sale	75.35	10,000	753,453	574,190	Jun 24 07:02 PM
Ho Tony W	Executive VP, Head of R&D	Jun 23	Sale	75.20	6,929	521,061	33,747	Jun 24 05:58 PM
Ho Tony W	Executive VP, Head of R&D	Jun 22	Sale	70.14	229	16,062	40,676	Jun 24 05:58 PM
Bolzon Bradley J PhD	Director	Jun 22	Sale	72.51	10,000	725,069	584,190	Jun 24 07:02 PM
Kulkarni Samarth	Chief Executive Officer	Jun 01	Option Exercise	1.81	17,275	31,268	188,801	Jun 03 05:32 PM
Kulkarni Samarth	Chief Executive Officer	Jun 01	Sale	64.68	17,275	1,117,266	171,526	Jun 03 05:32 PM
Ho Tony W	Executive VP, Head of R&D	May 26	Sale	70.14	6,100	427,854	40,905	May 27 04:32 PM
Novak Rodger	President	May 26	Sale	70.27	36,616	2,573,006	748,007	May 27 04:34 PM
Novak Rodger	President	May 22	Sale	70.01	13,384	937,014	784,623	May 27 04:34 PM
Ho Tony W	Executive VP, Head of R&D	May 22	Sale	70.05	600	42,030	47,005	May 27 04:32 PM
Kulkarni Samarth	Chief Executive Officer	May 20	Option Exercise	1.81	10,693	19,354	182,219	May 21 04:35 PM
Kulkarni Samarth	Chief Executive Officer	May 20	Sale	65.28	10,693	698,039	171,526	May 21 04:35 PM
Kulkarni Samarth	Chief Executive Officer	May 19	Option Exercise	1.81	4,307	7,796	175,833	May 21 04:35 PM
Novak Rodger	President	May 19	Sale	65.00	50,000	3,250,000	798,007	May 21 04:37 PM
Kulkarni Samarth	Chief Executive Officer	May 19	Sale	65.16	4,307	280,644	171,526	May 21 04:35 PM
Klein Lawrence Otto	CBO & COO	May 11	Option Exercise	5.86	25,000	146,500	45,000	May 13 04:38 PM
Klein Lawrence Otto	CBO & COO	May 11	Sale	60.40	25,000	1,509,971	20,000	May 13 04:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience